Novel Cation-Exchange Wound Dressing for Diabetic Ulcers

用于糖尿病溃疡的新型阳离子交换伤口敷料

• 批准号: 6834243
• 负责人: DAVID J VACHON
• 金额: $ 10.84万
• 依托单位: AEGIS BIOSCIENCES, LLC
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-09-30 至 2006-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6834243
• 关键词: amputation; angiogenesis; antibiotics; biomaterial development /preparation; biomaterial evaluation; biotechnology; cations; diabetes mellitus therapy; disease /disorder model; disease /disorder proneness /risk; drug delivery systems; fluid; foot; health care cost /financing; laboratory rat; nitric oxide; nonhuman therapy evaluation; polyethylene glycols; polymers; protease inhibitor; therapy design /development; ulcer; ultraviolet spectrometry; wound healing; wound infection

DESCRIPTION (provided by applicant): As many as 20 million people in the United States have diabetes and more than two million of these individuals will develop diabetic foot ulcers during their lifetime. In addition, the incidence of ulcer recurrence after complete healing approaches 30% within 12 months. The average cost for a single episode of a diabetic foot ulcer has been reported to be $4,595. Diabetic foot ulcers are very difficult to heal and represent a serious problem in this country. They are also a leading cause of hospitalization among those with diabetes. At any given time, up to 800,000 people in the U.S. suffer from them and these patients are at higher risk for infection, as well as amputation, with roughly 67,000 (diabetes-related) amputations conducted each year. Diabetic foot disease is estimated to cost the nation in excess of $1.2 billion [US] each year, excluding the costs of surgery, rehabilitation, prostheses, and lost income. It is clear that despite the medical advances that have been made in the treatment of diabetes in the past fifty years, there remains a significant need for more effective therapies to treat diabetic foot disease. With costs to treat these wounds reaching into the billions of dollars annually and rising, what is needed is a treatment that makes use of the fundamental understanding of (1) the underlying biology and biochemistry of these wounds and their mitigation, and application of this knowledge to (2) biomaterials science and controlled release technology, thus allowing for the treatment of these wounds in a rational & scientific manner. Furthermore, the treatment should provide a cost-conscious alternative to today's (expensive) therapies that in addition, relieves suffering for these "hard-to-hear' patients, and provides better overall patient outcomes. The development of a cost-effective, non-adherent novel hydrogel dressing that will remove fluid from the wound, add a low dose proteinase inhibitor and antibiotic, and/or nitric oxide precursor and angiogenic agent, and in addition acts to minimize noxious wound biomolecules by sequestration is described.

描述（由申请人提供）： 在美国，多达2000万人患有糖尿病，其中超过200万人在其一生中会患上糖尿病足溃疡。此外，溃疡完全愈合后12个月内复发率接近30%。据报道，糖尿病足溃疡单次发作的平均费用为4，595美元。糖尿病足溃疡是非常难以愈合，并代表了一个严重的问题，在这个国家。它们也是糖尿病患者住院的主要原因。在任何时候，美国都有多达80万人患有糖尿病，这些患者感染和截肢的风险更高，每年大约有67，000例（糖尿病相关）截肢。据估计，糖尿病足疾病每年花费超过12亿美元[美国]，不包括手术，康复，假肢和收入损失的费用。很明显，尽管在过去五十年中在糖尿病治疗方面取得了医学进步，但仍然非常需要更有效的治疗糖尿病足疾病的疗法。随着治疗这些伤口的成本每年达到数十亿美元并不断上升，需要的是一种利用对以下方面的基本理解的治疗：（1）这些伤口的基础生物学和生物化学及其缓解，以及将这些知识应用于（2）生物材料科学和控释技术，从而允许以合理和科学的方式治疗这些伤口。此外，治疗应该提供一个成本意识的替代今天的（昂贵的）治疗，此外，减轻痛苦的这些“重听”的患者，并提供更好的整体患者的结果。描述了一种成本有效的、非粘附性的新型水凝胶敷料的开发，该敷料将从伤口中去除流体，添加低剂量的蛋白酶抑制剂和抗生素，和/或一氧化氮前体和血管生成剂，并且另外通过隔离作用使有害的伤口生物分子最小化。